These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 2882282)

  • 21. At the receiving end of the lisuride pump.
    Todes CJ
    Lancet; 1986 Jul; 2(8497):36-7. PubMed ID: 2873331
    [No Abstract]   [Full Text] [Related]  

  • 22. Pergolide and lisuride for Parkinson's disease.
    Lieberman AN; Leibowitz M; Neophytides A; Kupersmith M; Mehl S; Kleinberg D; Serby M; Goldstein M
    Lancet; 1979 Nov; 2(8152):1129-30. PubMed ID: 91856
    [No Abstract]   [Full Text] [Related]  

  • 23. Bromocriptine and lisuride in Parkinson's disease.
    Caraceni T; Giovannini P; Parati E; Scigliano G; Grassi MP; Carella F
    Adv Neurol; 1984; 40():531-5. PubMed ID: 6695632
    [No Abstract]   [Full Text] [Related]  

  • 24. "On-off" phenomena, dyskinesias and dystonias. Comparison of lisuride versus apomorphine acute treatment.
    Frattola L; Albizzati MG; Bassi S; Ferrarese C; Trabucchi M
    Acta Neurol Scand; 1982 Aug; 66(2):227-36. PubMed ID: 7136487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease].
    Kreczy-Kleedorfer B; Wagner M; Bösch S; Poewe W
    Nervenarzt; 1993 Apr; 64(4):221-5. PubMed ID: 8506009
    [No Abstract]   [Full Text] [Related]  

  • 26. [Subcutaneous administration of apomorphine in motor fluctuations in Parkinson's disease].
    Pollak P; Champay AS; Gaio JM; Hommel M; Benabid AL; Perret J
    Rev Neurol (Paris); 1990; 146(2):116-22. PubMed ID: 2320817
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apomorphine test to predict dopaminergic responsiveness in parkinsonian syndromes.
    Hughes AJ; Lees AJ; Stern GM
    Lancet; 1990 Jul; 336(8706):32-4. PubMed ID: 1973218
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Apomorphine as adjuvant treatment in idiopathic Parkinson syndrome].
    Bösch MF; Ludin HP
    Schweiz Arch Neurol Psychiatr (1985); 1994; 145(5):8-13. PubMed ID: 7709189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Subcutaneous apomorphine infusion in the treatment of Parkinson disease].
    Albani C; Zangger I; Fischer G
    Schweiz Rundsch Med Prax; 1992 Aug; 81(35):1011-5. PubMed ID: 1410978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous dopaminergic stimulation: state of the art and outlook.
    Horowski R; Marsden CD; Obeso JA
    J Neural Transm Suppl; 1988; 27():249-52. PubMed ID: 3042911
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy of a low-dose subcutaneous lisuride infusion in Parkinson's disease.
    Hayashi R; Tako K; Makishita H; Koyama J; Yanagisawa N
    Intern Med; 1998 May; 37(5):444-8. PubMed ID: 9652898
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lisuride and pergolide in Parkinson's disease.
    Lang AE; Sheehy MP; Quinn NP; Brincat S; Marsden CD; Parkes D
    Adv Neurol; 1983; 37():109-20. PubMed ID: 6858769
    [No Abstract]   [Full Text] [Related]  

  • 33. Continuous intracerebroventricular infusion of dopamine and dopamine agonists through a totally implanted drug delivery system in animal models of Parkinson's disease.
    de Yebenes JG; Fahn S; Lovelle S; Jackson-Lewis V; Jorge P; Mena MA; Reiriz J; Bustos JC; Magariños C; Martinez A
    Mov Disord; 1987; 2(3):143-58. PubMed ID: 2904648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of Parkinson disease with Bromocriptine (CB 154 Sandoz) (author's transl)].
    Jacobides GB; Audibert A
    Ther Umsch; 1975 Jul; 32(7):469-71. PubMed ID: 1105868
    [No Abstract]   [Full Text] [Related]  

  • 35. Problems in daily motor performances in Parkinson's disease: the continuous dopaminergic stimulation.
    Stocchi F; Ruggieri S; Brughitta G; Agnoli A
    J Neural Transm Suppl; 1986; 22():209-18. PubMed ID: 3465872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. TRH test and the continuous dopaminergic stimulation in complicated Parkinson's disease.
    Lestingi L; Bonifati V; Stocchi F; Antonozzi I; Meco G
    Eur Neurol; 1992; 32(2):65-9. PubMed ID: 1563463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lisuride treatment in Parkinson's disease: clinical and pharmacokinetic studies.
    LeWitt PA; Burns RS; Calne DB
    Adv Neurol; 1983; 37():131-40. PubMed ID: 6344586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Subcutaneous apomorphine in Parkinson's disease: response to chronic administration for up to five years.
    Hughes AJ; Bishop S; Kleedorfer B; Turjanski N; Fernandez W; Lees AJ; Stern GM
    Mov Disord; 1993 Apr; 8(2):165-70. PubMed ID: 8474483
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients.
    Vaamonde J; Luquin MR; Obeso JA
    Brain; 1991 Feb; 114 ( Pt 1B)():601-17. PubMed ID: 2004258
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Lactation inhibition with various dosages of lisuride--prolactin secretion and effectiveness].
    Strahl HJ; Göretzlehner G; Strahl S; Kunkel S
    Zentralbl Gynakol; 1985; 107(5):300-3. PubMed ID: 4039514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.